EGFR and neoplasm: However, even when only 267 patients whose tumor EGFR mutation status had been molecularly determined by standard methods were examined, clinicopathological features based on PD-L1 expression and PD-L1 copy number were similar to results from the entire cohort (Supplementary Table S4).